Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.

On Thursday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $122.41 which represents a slight increase of $4.42 or 3.75% from the prior close of $117.99. The stock opened ...

Analyst Uy Ear from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $177.83, a high ...

We recently published a list of the 7 Best Revenue Growth Stocks to Buy According to Analysts. In this article, we are going ...

These two could become direct competitors relatively soon.

Sarepta dominates the Duchenne muscular dystrophy market. Find out why recent insider buying of SRPT stock may signal ...

The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ...

COLUMN: ‘Among many heroes in the broad societal programme to imagine and construct new futures for South Africans, as ...

Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $120.4 which represents a slight increase of $1.64 or 1.38% from the prior close of $118.76. The stock opened at $119.91 ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Prime Medicine's layoffs are part of a pattern. At least a half-dozen gene-editing companies have laid off staff in the past ...